The field of immunotherapy is celebrating with well-justified pride on the recent regulatory approvals of PD-1/PD-L1 blocking agents for a number of new malignant tumor indications, as well as of the adoptive transfer of CAR-T cells gene-targeted to CD19, which are amazingly efficacious for the treatment of children with refractory acute lymphoid leukemia as well as adult patients with relapsed or refractory large B-cell lymphoma. Patients with advanced metastatic tumors of many kinds are not only responding but also achieve long-lasting remission. Such clinical efficacy results are certainly unprecedented in oncology but, even if dazzled, we must move on. In the January issue of Annals of Oncology, Shalabi et al. provide an analysis of the magnitude of the global immunotherapy effort with a comprehensive survey of public data estimating the number of clinical trials, agents and the investment volumes. This is to be taken only as an indication of the prominence and priority of the cancer immunotherapy field in both academia and industry [1].

中文翻译：

---

癌症免疫疗法全速前进

对PD-1 / PD-L1阻断剂在许多新的恶性肿瘤适应症以及以基因为靶点的CAR-T细胞的过继转移方面的最新法规批准，免疫疗法领域正以充分的自豪感为庆祝CD19可以有效治疗难治性急性淋巴白血病儿童以及成年复发或难治性大B细胞淋巴瘤患者。患有多种晚期转移性肿瘤的患者不仅反应良好，而且可以长期缓解。这样的临床疗效结果在肿瘤学上无疑是史无前例的，但是即使眼花azz乱，我们也必须继续前进。在《肿瘤学年刊》一月号中，Shalabi等。通过对公共数据进行全面调查，提供对全球免疫疗法工作规模的分析，以估计临床试验，代理商的数量和投资额。这只是作为学术界和工业界癌症免疫治疗领域的重要地位和优先考虑的标志[1]。